tiprankstipranks
AstraZeneca PLC (GB:AZN)
LSE:AZN

AstraZeneca (AZN) Share Price & Analysis

363 Followers

AZN Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range9,314.90p - 12,704.00p
Previous Close12,244p
Volume170.48K
Average Volume (3M)2.05M
Market Cap
£189.81B
Enterprise Value207.40B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)37.7
Beta0.87
Jul 25, 2024
Dividend Yield1.88%
Share Statistics
EPS (TTM)3.25
Shares Outstanding1,550,189,338
10 Day Avg. Volume2,944,327
30 Day Avg. Volume2,050,952
Standard Deviation0.06
R-Squared0.09
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-12.86
Price to Sales (P/S)486.49
Price to Cash Flow (P/CF)22.20
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.68
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda22.83
Forecast
13,203.18p
Price Target Upside8.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17

Bulls Say, Bears Say

Bulls Say
Pipeline PotentialAZN has 5 game-changing Phase III reads for key assets with a total sales potential of around $20 billion.
Revenue And ReratingAZN's new mid-term guide implies 30E revenues 20% above consensus and 30E EBIT at the bottom end of margin guide 10% above consensus.
Sales GrowthSolid key sales drivers (Imfinzi +14%, Farxiga +25%, Fasenra +4%), with a notable acceleration in oral oncology franchises (Tagrisso +6%, Lynparza +5%, Calquence +14%).
Bears Say
Competitive LandscapeJNJ's SubQ Rybrevant represents a more convenient and tolerable offering than IV, likely increasing competition for MARIPOSA in NSCLC.
Financial GuidanceThe company updated currency assumptions, now expecting a mid single digit adverse impact on core EPS.
Regulatory ApprovalThere is no statistically significant overall survival benefit in the intent-to-treat overall population, raising questions about FDA acceptance.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.16%14.72%8.57%76.55%
8.57% Other Institutional Investors
76.55% Public Companies and
Individual Investors

AZN FAQ

What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9314.90p and its highest was 12704.00p in the past 12 months.
    What is AstraZeneca PLC’s market cap?
    Currently, no data Available
    When is AstraZeneca PLC’s upcoming earnings report date?
    AstraZeneca PLC’s upcoming earnings report date is Jul 25, 2024 which is in 7 days.
      How were AstraZeneca PLC’s earnings last quarter?
      AstraZeneca PLC released its earnings results on Apr 25, 2024. The company reported 1.584p earnings per share for the quarter, beating the consensus estimate of 1.47p by 0.115p.
        Is AstraZeneca PLC overvalued?
        According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does AstraZeneca PLC pay dividends?
          AstraZeneca PLC pays a Annually dividend of 156p which represents an annual dividend yield of 1.88%. See more information on AstraZeneca PLC dividends here
            What is AstraZeneca PLC’s EPS estimate?
            AstraZeneca PLC’s EPS estimate is £1.53.
              How many shares outstanding does AstraZeneca PLC have?
              AstraZeneca PLC has 1,550,268,100 shares outstanding.
                What happened to AstraZeneca PLC’s price movement after its last earnings report?
                AstraZeneca PLC reported an EPS of 1.584p in its last earnings report, beating expectations of 1.47p. Following the earnings report the stock price went up 5.937%.
                  Which hedge fund is a major shareholder of AstraZeneca PLC?
                  Currently, no hedge funds are holding shares in GB:AZN
                  ---

                  AstraZeneca Stock Smart Score

                  Company Description

                  AstraZeneca PLC

                  A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
                  ---

                  AZN Stock 12 Month Forecast

                  Average Price Target

                  13,203.18p
                  ▲(8.92% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6612":"6,612p","17701":"17,701p","9384.25":"9,384.3p","12156.5":"12,156.5p","14928.75":"14,928.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13203.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6613.572,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6612,9384.25,12156.5,14928.75,17701],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12056,12490.153846153846,12924.307692307691,13358.461538461539,13792.615384615385,14226.76923076923,14660.923076923076,15095.076923076922,15529.23076923077,15963.384615384615,16397.53846153846,16831.69230769231,17265.846153846152,{"y":17700,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12056,12144.244615384616,12232.489230769232,12320.733846153846,12408.978461538461,12497.223076923077,12585.467692307693,12673.712307692307,12761.956923076923,12850.201538461539,12938.446153846155,13026.690769230769,13114.935384615384,{"y":13203.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12056,11637.351692307693,11218.703384615384,10800.055076923078,10381.406769230769,9962.758461538462,9544.110153846153,9125.461846153847,8706.813538461538,8288.165230769231,7869.516923076923,7450.868615384616,7032.220307692308,{"y":6613.572,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10099.3,"date":1689292800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10672.55,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10534.77,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10773.03,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10111.4,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10040.52,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10591.87,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10200.02,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10080,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10620,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12050,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12556,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12056,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  GlaxoSmithKline
                  Smith & Nephew
                  EKF Diagnostics Holdings

                  Best Analysts Covering AZN

                  1 Year
                  Emily FieldBarclays
                  1 Year Success Rate
                  30/36 ratings generated profit
                  83%
                  1 Year Average Return
                  +13.86%
                  reiterated a buy rating 9 days ago
                  Copying Emily Field's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +13.86% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis